And, with two NIH-funded Stage IIB trials starting at Drexel University soon, the hope is that PRO 140 can eventually be developed into an effective post-exposure therapy delivered viainjection once a week or a few times a month versus the current cocktail of pills available to patients today.
However, potentially one of the most significant advances is the possibility of a vaccine deliverable via a nasal spray rather than requiring injection by a trained medical worker.